PegBio Co (2565.HK) Stock Price

PegBio Co Price

CLOSED
2.77
​
Market closed

The consensus 12-month price target for PegBio Co is 10.43 CNY, about 276.6% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

PegBio Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co business model & stock analysis

PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions.

Frequently asked questions about PegBio Co

Analysts currently set an average price target of 10.43 CNY for the PegBio Co stock (median: 10.43 CNY), implying +280.1 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the PegBio Co stock: 0 recommend buying, 2 holding and 7 selling.

Converted at the current exchange rate, the PegBio Co share trades at 0.38 EUR (2.77 CNY).

The revenue cannot currently be calculated for PegBio Co.

The expected profit of PegBio Co is -146.57 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PegBio Co is currently -7.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PegBio Co stock.

The P/S cannot be calculated for PegBio Co currently.

The Eulerpool Quality Score for PegBio Co is 2/10.

The ISIN of PegBio Co is CNE100006T44. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of PegBio Co is 2565.HK. The ticker symbol is used to trade PegBio Co shares on the stock exchange.

Fair ValueTerminal
2.55 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pegbio.com
Country
Currency
CNY
Initial public offering
May 27, 2025
ISIN
CNE100006T44
Cusip
Y6725L107
Market capitalization
1.08 B CNYSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-7.39
P/Ee 2027
-17.40
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.42
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-46.46 %
Last updated Nov 17, 2026, 3:41 AM

PegBio Co Peer Group

All fundamentals and in-depth analysis of PegBio Co

Our stock analysis for PegBio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PegBio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.